TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharmaust Limited ( (AU:NUZ) ) has provided an update.
Neurizon Therapeutics Limited has issued 150,000 fully paid ordinary shares following the exercise of unlisted options at an exercise price of $0.10 each. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions. This move is part of Neurizon’s broader strategy to enhance its financial position as it continues to develop its lead drug candidate, NUZ-001, for ALS treatment, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is advancing its lead drug candidate, NUZ-001, for the treatment of ALS, the most common form of motor neurone disease. Neurizon aims to accelerate access to effective ALS treatments and explore broader neurodegenerative applications through international collaborations and rigorous clinical programs.
Average Trading Volume: 775,672
Technical Sentiment Signal: Sell
Current Market Cap: A$58.8M
See more insights into NUZ stock on TipRanks’ Stock Analysis page.